Differential interaction of 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors with ABCB1, ABCC2, and OATP1B1

Drug Metabolism and Disposition

Volumn 33, Issue 4, 2005, Pages 537-546

  Chen, Cuiping ^a,b   Mireles, Rouchelle J ^a   Campbell, Scott D ^a   Lin, Jian ^a   Mills, Jessica B ^a   Xu, Jinghai J ^a   Smolarek, Teresa A ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCC2 PROTEIN; ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; MULTIDRUG RESISTANCE PROTEIN 1; OATP1B1 PROTEIN; PRAVASTATIN; SIMVASTATIN; UNCLASSIFIED DRUG;

ANIMAL CELL; APICAL MEMBRANE; ARTICLE; BASOLATERAL MEMBRANE; BINDING AFFINITY; BINDING KINETICS; CELL CULTURE; CONTROLLED STUDY; DRUG PROTEIN BINDING; DRUG TRANSPORT; IC 50; INHIBITION KINETICS; KIDNEY CELL; MEMBRANE PERMEABILITY; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSPORT KINETICS;

ADENOSINE TRIPHOSPHATE; ANIMALS; CELL LINE; DOGS; ESTRADIOL; FLUORESCEINS; HEPTANOIC ACIDS; HYDROLYSIS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LOVASTATIN; MEMBRANE TRANSPORT PROTEINS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; ORGANIC ANION TRANSPORTERS; P-GLYCOPROTEIN; PERMEABILITY; PYRROLES; SIMVASTATIN; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 15344341734     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: 10.1124/dmd.104.002477     Document Type: Article

References (41)

1. Backman JT, Kyrklund C, Neuvonen M, and Neuvonen PJ (2002) Gemfibrozil greatly increases plasma concentrations of cerivastatin. Clin Pharmacol Ther 72:685-691.
2. Billecke S, Draganov D, Counsel R, Stetson P, Watson C, Hsu C, and La Du BN (2000) Human serum paraoxonase (pon1) isozymes Q and R hydrolyze lactones and cyclic carbonate esters. Drug Metab Dispos 28:1335-1342.
3. Bogman K, Peyer AK, Török M, Küsters E, and Drewe J (2001) HMG-CoA reductase inhibitors and P-glycoprotein modulation. Br J Pharmacol 132:1183-1192.
4. Borst P, Evers R, Kool M, and Wijnholds J (1999) The multidrug resistance protein family. Biochim Biophys Acta 1461:347-357.
5. Boyd RA, Stern RH, Stewart BH, Wu X, Reyner EL, Zegarac EA, Randinitis EJ, and Whitfield L (2000) Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein-mediated secretion. J Clin Pharmacol 40:91-98.
6. Brockman AH, Hiller DL, and Cole RO (2000) High-speed HPLC/MS/MS analysis of biological fluids: a practical review. Curr Opin Drug Dev 3:432-438.
7. Chen C, Hanson E, Watson J, and Lee J (2003a) P-glycoprotein limits the brain penetration of nonsedating but not sedating H1-antagonists. Drug Metab Dispos 31:312-318.
8. Chen C, Liu X, and Smith BJ (2003b) Utility of mdr1 gene-deficient mice in drug discovery and development. Curr Drug Metab 4:272-291.
9. Chen C and Pollack GM (1999) Enhanced antinociception of the model opioid peptide [D-penicillamine] enkephalin by P-glycoprotein modulation. Pharm Res (NY) 16:296-301.
10. Chen C, Scott D, Hanson E, Volberg M, Berryman E, and Liu X (2003c) Impact of Mrp2 on biliary excretion and intestinal absorption of furosemide, probenecid and methotrexate using Eisai Hyperbilirubinemic rats. Pharm Res (NY) 20:31-37.
11. Corsini A, Bellosta S, Baetta R, Fumagalli R, Paoletti R, and Bernini F (1999) New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther 84:413-428.
12. Draganov DI, Stetson PL, Watson CE, Billecke SS, and La Du BN (2000) Rabbit serum paraoxonase 3 (pon3) is a high density lipoprotein-associated lactonase and protects low density lipoprotein against oxidation. J Biol Chem 275:33435-33442.
13. Hagenbuch B and Meier PJ (2004) Organic anion transporting polypeptides of the OATP/SLC21 family: phylogenetic classification as OATP/SLCO superfamily, new nomenclature and molecular/functional properties. Pflueg Arch Eur J Physiol 447:653-665.
14. Hall SD, Thummel KE, Watkins PB, Lown KS, Benet LZ, Paine MF, Mayo RR, Turgeon DK, Bailey DG, Fontana RJ, et al. (1999) Molecular and physical mechanisms of first-pass extraction. Drug Metab Dispos 27:161-166.
15. Hatanaka T (2000) Clinical pharmacokinetics of pravastatin. Mechanisms of pharmacokinetic events. Clin Pharmacokinet 39:397-412.
16. Hsiang B, Zhu Y, Wang Z, Wu Y, Sasseville V, Yang W, and Kirchgessner TG (1999) A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J Biol Chem 274:37161-37168.
17. Ishigami M, Honda T, Takasaki W, Ikeda T, Komai T, Ito K, and Sugiyama Y (2001) A comparison of the effects of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors on the CYP3A4-dependent oxidation of mexazolam in vitro. Drug Metab Dispos 29:282-288.
18. Kantola T, Kivisto KT, and Neuvonen PJ (1998a) Effect of itraconazole on the pharmacokinetics of atorvastatin. Clin Pharmacol Ther 64:58-65.
19. Kantola T, Kivisto KT, and Neuvonen PJ (1998b) Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther 64:177-182.
20. Kyrklund C, Backman JT, Kivisto KT, Neuvonen M, Laitila J, and Neuvonen PJ (2001) Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate. Clin Pharmacol Ther 69:340-345.
21. 6-fold increased cell sensitivity to verocytotoxin. Role of P-glycoprotein in glycolipid synthesis. J Biol Chem 275:6246-6251.
22. Lennernas H and Fager G (1997) Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Clin Pharmacokinet 32:403-425.
23. Mazzu AL, Lasseter KC, Shamblen EC, Agarwal V, Lettieri J, and Sundaresen P (2000) Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin. Clin Pharmacol Ther 68:391-400.
24. Mottino AD, Hoffman T, Jennes L, and Vore M (2000) Expression and localization of multidrug resistant protein mrp2 in rat small intestine. J Pharmacol Exp Ther 293:717-723.
25. Muck W, Mai I, Fritsche L, Ochmann K, Rohde G, Unger S, Johne A, Bauer S, Budde K, Roots I, et al. (1999) Increase in cerivastatin systemic exposure after single and multiple dosing in cyclosporine-treated kidney transplant recipients. Clin Pharmacol Ther 65:251-261.
26. Neuvonen PJ and Jalava KM (1996) Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther 60:54-61.
27. Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, and Serabjit-Singh CS (2001) Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther 299:620-628.
28. Prueksaritanont T, Subramanian R, Fang X, Ma B, Qiu Y, Lin JH, Pearson PG, and Baillie TA (2002a) Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization. Drug Metab Dispos 30:505-512.
29. Prueksaritanont T, Zhao JJ, Ma B, Roadcap BA, Tang C, Qiu Y, Liu L, Lin JH, Pearson PG, and Baillie TA (2002b) Mechanistic studies on metabolic interactions between gemfibrozil and statins. J Pharmacol Exp Ther 301:1042-1051.
30. Reinoso RF, Sanchez NA, Garcia MJ, and Prous JR (2001) Pharmacokinetic interactions of statins. Methods Find Exp Clin Pharmacol 23:541-566.
31. Scarborough GA (1995) Drug stimulated ATPase activity of the human P-glycoprotein. J Bioenerg Biomembr 27:37-41.
32. Shapiro AB, Fox K, Lam P, and Ling V (1999) Stimulation of P-glycoprotein-mediated drug transport by prazosin. Eur J Biochem 259:841-850.
33. Shitara Y, Hirano M, Sato H, and Sugiyama Y (2004) Gemfibrozil and its glucuronide inhibit the OATP2 (OATP1B1: SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil. J Pharmacol Exp Ther 311:228-236.
34. Shitara Y, Itoh T, Sato H, Li AP, and Sugiyama Y (2003) Inhibition of transporter-mediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporin A. J Pharmacol Exp Ther 304:610-616.
35. Smith BJ, Doran AC, Mclean S, Tingley FD, O'Nell BT, and Kajiji SM (2001) P-glycoprotein efflux at the blood-brain barrier mediates differences in brain disposition and pharmacodynamics between two structurally related neurokinin-1 receptor antagonists. J Pharmacol Exp Ther 298:1252-1259.
36. Stockley IH (1999) Drug Interactions. A Source Book of Adverse Interactions, Their Mechanisms, Clinical Importance and Management. Pharmaceutical Press. London.
37. Tirona RG, Leake BF, Wolkoff AW, and Kim RB (2003) Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation. J Pharmacol Exp Ther 304:223-228.
38. Wang EJ, Casciano CN, Clement RP, and Johnson WW (2001) HMG-CoA reductase inhibitors (statins) characterized as direct inhibitors of P-glycoprotein. Pharm Res (NY) 18:800-806.
39. Wu X, Whitfield LR, and Steart BH (2000) Atorvastatin transport in the Caco-2 model: contribution of P-glycoprotein and the proton-monocarboxylic acid co-transporter. Pharm Res (NY) 17:209-215.
40. Yamazaki M, Akiyama S, Ni'inuma K, Nishigaki R, and Sugiyama Y (1997) Biliary excretion of pravastatin in rats: contribution of the excretion pathway mediated by canalicular multi-specific organic anion transporter (CMOAT). Drug Metab Dispos 25:1123-1129.
41. Zhang Y, Guo X, Lin ET, and Benet LZ (1998) Overlapping substrate specificities of cytochrome P450 3A and P-glycoprotein for a novel cysteine protease inhibitor. Drug Metab Dispos 26:360-366.